The HemOnc Pulse cover image

Part One: The Question of MRD in CLL Therapy

The HemOnc Pulse

CHAPTER

Comparative Analysis of BTK Inhibitors for CLL Therapy and Treatment Options

This chapter analyzes the differences between acalabrutinib and zanabrutenev as BTK inhibitors for CLL treatment, considering factors like efficacy, dose reduction, and switching options in light of evolving treatment choices.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner